Tesofensine: Tesofensine is a triple-monoamine reuptake inhibitor originally developed for neurodegenerative disorders but repurposed for obesity treatment. Clinical pharmacokinetics show an elimination half-life of ≈220 hours with an active N-desalkyl metabolite (NS2360) lasting ≈374 hours; steady-
Related pages